Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

Alan F. Cohen; Christopher J. Hartnick; Richard V. Smith

doi:10.1177/000348949710600804

Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

Alan F. Cohen, Christopher J. Hartnick, Richard V. Smith

Otorhinolaryngology - Head & Neck Surgery

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

Original language	English (US)
Pages (from-to)	640-642
Number of pages	3
Journal	Annals of Otology, Rhinology and Laryngology
Volume	106
Issue number	8
DOIs	https://doi.org/10.1177/000348949710600804
State	Published - 1997

Keywords

Immunosuppression
OKT3
Sensorineural hearing loss
Transplant

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1177/000348949710600804

Cite this

@article{d594d609bc5147aaaf71e24dbb6ba7a9,

title = "Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)",

abstract = "Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.",

keywords = "Immunosuppression, OKT3, Sensorineural hearing loss, Transplant",

author = "Cohen, {Alan F.} and Hartnick, {Christopher J.} and Smith, {Richard V.}",

year = "1997",

doi = "10.1177/000348949710600804",

language = "English (US)",

volume = "106",

pages = "640--642",

journal = "Annals of Otology, Rhinology and Laryngology",

issn = "0003-4894",

publisher = "Annals Publishing Company",

number = "8",

}

TY - JOUR

T1 - Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

AU - Cohen, Alan F.

AU - Hartnick, Christopher J.

AU - Smith, Richard V.

PY - 1997

Y1 - 1997

N2 - Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

AB - Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

KW - Immunosuppression

KW - OKT3

KW - Sensorineural hearing loss

KW - Transplant

UR - http://www.scopus.com/inward/record.url?scp=8544245667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544245667&partnerID=8YFLogxK

U2 - 10.1177/000348949710600804

DO - 10.1177/000348949710600804

M3 - Article

C2 - 9270425

AN - SCOPUS:8544245667

SN - 0003-4894

VL - 106

SP - 640

EP - 642

JO - Annals of Otology, Rhinology and Laryngology

JF - Annals of Otology, Rhinology and Laryngology

IS - 8

ER -

Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this